Studies on intrahepatic cholangiocarcinoma observed poor prognosis and significantly high tumor mutational burden among the patients having a co-mutation of KRAS and TP53 compared to the wild type and single-mutation-harboring patients [108]. The gene discussed is KRAS; the disease is neoplasm.